Tumor cells undergoing ICD can be used as vaccines or as immune adjuvants to attract and promote DCs maturation, which in turn acts as powerful antigen-presenting cells (APCs) to activate adaptive immune responses, particularly CD8 killer T cells and CD4 helper T cells [4]. Here, CD8A is linked to neoplasm.